DiaCarta Enters Contract with the VA Health Care System (San Francisco) for VEXAS Syndrome Testing

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PLEASANTON, Calif., Oct. 3, 2024 /PRNewswire/ — DiaCarta, a leading molecular diagnostic company specializing in oncology and infectious disease tests, announces today that it has entered into a diagnostic testing service contract with the Department of Veterans Affairs San Francisco VA Health Care System (SFVAHCS). Under this contract, DiaCarta will provide the VEXAS syndrome testing for Veterans within the VA healthcare system, starting October 1, 2024. The QClamp® Plex VEXAS test was developed at DiaCarta using its XNA technology and validated at its CAP/CLIA laboratory.

  • VEXAS Syndrome, discovered in 2020, is an autoinflammatory disease characterized by inflammation affecting various tissues and organs (joints, cartilage, skin, vessels, lungs, etc.), bone marrow failure (progressive anemia with large red cells, thrombocytopenia, etc.), and high risk for clotting (both venous and arterial). Due to its diverse presentations, patients with the disease may be seen by doctors in various clinical specialties (e.g., Hematology, Rheumatology, Dermatology, ENT, Pulmonology, Pathology). VEXAS is often undiagnosed or misdiagnosed as other conditions such as Relapsed Polychondritis (RP), Myelodysplastic Syndrome (MDS), Sweet Syndrome, or Vasculitis, which exhibit similar symptoms and physical signs.
  • VEXAS Syndrome is distinguished by specific somatic gene mutations, which are not found in patients with other diseases. Identifying the unique mutations in a gene called UBA1 allows physicians to accurately diagnose VEXAS Syndrome and appropriately treat and manage those patients. Experts strongly recommend testing all patients with clinical manifestations suggesting VEXAS syndrome. The disease typically occurs in men older than 50 (prevalence is 1 in 4000), but the disease is also rarely seen in women.

“We are excited about the contract with SFVAHCS and the opportunity to serve our Veterans,” said Dr. Adam (Aiguo) Zhang, President and CEO of DiaCarta. “Our novel QClamp® Plex technology overcomes key challenges in VEXAS syndrome testing, including sensitivity, turnaround time and cost. By reducing patient wait times and increasing diagnostic accuracy, we aim to alleviate the anxiety associated with uncertain diagnoses and support physicians in developing effective treatment strategies.”

About DiaCarta:

DiaCarta is a molecular in-vitro diagnostics (IVD) company that has developed innovative technologies that transform patient care by providing effective precision diagnostics using liquid biopsy. Its novel XNA technology provides a high level of sensitivity as it binds to the wild-type sequence, which enables only the mutant target sequence to be amplified. Its isobDNA technology provides a high level of detection as it amplifies the signal and requires no RNA/DNA extraction or amplification. Based in Pleasanton, California, the company is ISO-certified, GMP-compliant, and offers CLIA-certified and CAP-accredited laboratory services to its customers. www.diacarta.com

Contact:

Claudia Li
Sr. Manager of Digital Marketing
DiaCarta, Inc.
384232@email4pr.com
415-570-3886

View original content to download multimedia:https://www.prnewswire.com/news-releases/diacarta-enters-contract-with-the-va-health-care-system-san-francisco-for-vexas-syndrome-testing-302266750.html

SOURCE DiaCarta Inc.

Staff

Recent Posts

Edison Issues Report on Electro Optic Systems (EOS)

London, United Kingdom--(Newsfile Corp. - June 10, 2025) - Edison issues report on Electro Optic…

51 minutes ago

Santiam Hospital and Clinics enters into Prime Vendor agreement with Medline

Oregon-based hospital taps into Medline's custom pack capabilities and distribution services NORTHFIELD Ill., June 9,…

12 hours ago

20/20NOW Advances Tele-Optometry with New VP of Professional Services Dr. Noelle Tchang OD and Spotlights Telehealth at Digital EyeCon

HOLBROOK, N.Y., June 9, 2025 /PRNewswire/ -- 20/20NOW, a pioneer in ocular telehealth, proudly announces…

12 hours ago

Business Integra Launches Mission-Ready Healthcare Staffing Solutions Backed by AI Technology

BETHESDA, Md., June 9, 2025 /PRNewswire/ -- Business Integra (BI), a leader in mission-critical talent solutions,…

12 hours ago

Imre Introduces the AI Conversation Converter

Agency launches First-in-Kind platform to quickly insert healthcare brands directly into the AI conversation NEW…

12 hours ago